Health Care Distributors

NEPTUNUS

NEPTUNUS released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 5.945 B, actual EPS CNY 0.0055

NEPTUNUS released FY2025 Annual Earnings on April 28 After-Market (BJT), with actual revenue of CNY 26.67 B and EPS of CNY -0.214

NEPTUNUS released FY2025 Q4 earnings on April 28 After-Market (BJT), actual revenue CNY 5.155 B, actual EPS CNY 0

NEPTUNUS to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

NEPTUNUS FY2025 Annual Earnings Release on April 29 After-Market BJT

NEPTUNUS released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 7.201 B, actual EPS CNY -0.0023

NEPTUNUS released FY2025 9-month earnings on October 29 After-Market BJT, actual revenue CNY 21.51 B, actual EPS CNY 0.0097

NEPTUNUS FY2025 Q3 Earnings Release on October 30, 2025, After-Market (BJT)

NEPTUNUS released FY2025 Q2 earnings on August 29 During-Market (BJT), actual revenue CNY 6.936 B, actual EPS CNY 0.003

NEPTUNUS released FY2025 Semi-Annual Earnings on August 29 During-Market (BJT), actual revenue CNY 14.31 B, actual EPS CNY 0.012

NEPTUNUS FY2025 Semi-Annual Earnings Release on August 30, 2025, Pre-Market BJT

Investors Question Hailiang Bio's Stock Performance and Business Operations

Hai Wang Pharmaceutical Research Institute's HW130 Injection Completes Phase I Clinical Trial

Haiwang Biologics Terminates A-Share Issuance

Haiwang Bio Terminates Control Rights Transfer and Stock Issuance

Two New Companies Under Hainan Wang Establishments

NEPTUNUS released FY2024 Q4 earnings on April 28 Pre-Market (BJT), actual revenue CNY 5.765 B, actual EPS CNY -0.4684

NEPTUNUS released FY2024 annual earnings on April 28 Pre-Market (BJT), actual revenue CNY 30.32 B, actual EPS CNY -0.4536

NEPTUNUS released FY2025 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 7.376 B, actual EPS CNY 0.009

NEPTUNUS FY2025 Q1 Earnings Release Scheduled for April 29 After-Market BJT

512290

002038

002923

000078

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn

Guotai CSI Bio-medicine ETF

SL PHARM

Rundu Pharma

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

RemeGen

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Sunshine Guojian Pharmaceutical

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

HITECK

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Cosunter

600829

600272

000411

002589

Pharmaceutical commercial stocks are repeatedly active, NEPTUNUS has a 6-day consecutive limit-up, Realcan hits the limit-up, HRPC, SHKK, INT'L GROUP, and others follow suit. In news, China's drug price registration system has officially launched

HRPC

SHKK

INT'L GROUP

Realcan

NEPTUNUS announced that its wholly-owned subsidiary has completed Phase I clinical trials for the HW130 injection and obtained the Phase I clinical research report. HW130 is a novel anti-tumor drug with independent intellectual property rights, and has received clinical trial approval from the National Medical Products Administration and the U.S. FDA. The drug has shown good safety and tolerability in patients with advanced malignant solid tumors, providing a basis for subsequent clinical trials

Zhitong

NEPTUNUS: HW130 injection completed Phase I clinical trial

NEPTUNUS announced the termination of the change of control matter and the cancellation of relevant agreements with Silk Spun Group and NEPTUNUS Group. At the same time, the company decided to terminate the issuance of A-shares to specific objects and signed an agreement to terminate the share subscription agreement

NEPTUNUS terminates the matter of change in control

000705

000950

002727

000028

The pharmaceutical commercial sector saw a short-term surge, with YIXINTANG hitting the limit up, and Sinopharm Accord, NEPTUNUS, INT'L GROUP, ZHEJIANG ZHENYUAN, CQP, and others all rising

ZHEJIANG ZHENYUAN

YIXINTANG

Sinopharm Accord

The pharmaceutical commercial sector has seen a short-term surge, with YIXINTANG hitting the limit up

NEPTUNUS announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute has received approval from the National Medical Products Administration to conduct clinical trials of NEP018 tablets in patients with advanced malignant solid tumors. NEP018 tablets are a new type of tumor-targeted small molecule kinase inhibitor with independent intellectual property rights, demonstrating good inhibitory effects on gastrointestinal tumors, aimed at meeting clinical needs. The core patent of this project has been granted an invention patent

United Therap

NEPTUNUS: NEP018 tablets have received the drug clinical trial approval notice

301017

603939

605266

603883

The AI medical concept continues to strengthen, driving the pharmaceutical commercial sector to be active in the afternoon. LBX reached the daily limit, while NEPTUNUS, JZJ, HRPC, SYPM, and Yifeng Pharmacy saw significant gains

SYPM

Yifeng Pharmacy

The pharmaceutical commercial sector is active against the trend, LBX hits the daily limit in the afternoon

NEPTUNUS expects a net loss of RMB 950 million to RMB 1.2 billion for the fiscal year 2024, mainly affected by the national healthcare system reform, centralized procurement policies, and price reductions from medical insurance negotiations. The company is facing operational management pressure, with major hospital clients experiencing tight funds, leading to an extended accounts receivable collection period, which affects the efficiency of working capital turnover, thereby reducing operating scale and profits

PKU HEALTHCARE

B-Soft

Winning Health

HUA MEDICINE-B

NEPTUNUS expects a pre-loss, with a projected net loss of 950 million to 1.2 billion yuan for the fiscal year 2024

NEPTUNUS(000078.SZ)